Author(s)
Rochau U1, Mühlberger N2, Qerimi V3, Weger R4, Hackl M5, Willenbacher W6, Siebert U7
1UMIT - University for Health Sciences, Medical Informatics and Technology, Department of Public Health, Health Services Research and Health Technology Assessment/ONCOTYROL - Center for Personalized Cancer Medicine, Area Health Technology Assessment, Hall i.T./Innsbruck, Austria, 2UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, Hall i.T., Austria, 3UMIT - University for Health Sciences, Medical Informatics and Technology, Department of Public Health, Health Services Research and Health Technology Assessment/Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy, Skopje, Macedonia, Hall i.T., Austria, 4ONCOTYROL - Center for Personalized Cancer Medicine, Area Health Technology Assessment, Innsbruck, Austria, 5Statistics Austria, Austrian National Cancer Registry, Directorate Social Statistics, Statistics Austria, Vienna, Austria, 6ONCOTYROL - Center for Personalized Cancer Medicine, Area Health Technology Assessment/Internal Medicine V—Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria, 7and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria
OBJECTIVES: To provide an overview on epidemiology and disease burden of multiple myeloma (MM) in Austria. METHODS: A systematic literature search was conducted in Pubmed/MEDLINE to identify relevant data on epidemiological measures (e.g., incidence, survival) for MM in Austria and other countries (to derive estimations in the absence of Austrian data). We included studies from Europe and the US reporting epidemiological measures published after 2004. Additionally, we searched (inter-)national databases (e.g., Statistik Austria, Austrian Myeloma Registry, International Agency for Research on Cancer) and bibliographies of retrieved publications. Data were summarized in evidence tables and diagrams. Furthermore, we used longitudinal survival data provided by Statistik Austria to show the effect of MM on overall survival and to estimate life years lost (YLL) due to MM. RESULTS: Our literature search yielded five studies. One study reported incidence and survival for Tyrol/Austria, one study reported incidence and mortality data for Europe, one study reported mortality data for Spain, and two studies presented US data. We identified seven databases reporting Austrian epidemiological measures. Statistik Austria reported age-standardized rates (ASR) for incidence (range: 2.6-3.0/100,000) and ASR for mortality (range: 1.6-2.0/100,000) for 2002-2012; 1-year and 5-year relative cumulative survival (73.1 and 42.1, 2005-2009). Prevalence ranged between 1,154 and 2,071 (2000-2012). Our analysis showed that between 1986 and 2010 the median survival of patients <65 years of age increased from 3.3 to 6.6 years. Estimated YLL within a 15-year period after diagnosis per MM patient declined from 9.8 (1983) to 8.6 (1999). However, the decrease of individual YLL is counterbalanced by increased incidence. In total, about 3000 life years are lost due to MM in Austria each year. CONCLUSIONS: We identified several publications/databases reporting epidemiological measures for MM in Austria. Annually, around 3000 life years are lost due to MM, potentially declining over time.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PSY28
Topic
Clinical Outcomes, Epidemiology & Public Health
Topic Subcategory
Relating Intermediate to Long-term Outcomes
Disease
Systemic Disorders/Conditions
